Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes
SNDX-5613-0708
Phase 1 other active
Quick answer
Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes for Acute Myeloid Leukemias is a Phase 1 program (other) at Syndax Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals
- Indication
- Acute Myeloid Leukemias
- Phase
- Phase 1
- Modality
- other
- Status
- active